Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Co-careldopa
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-careldopa 25mg/100mg tablets
0409010N0AAABAB
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 66,162 |
|
Co-careldopa 12.5mg/50mg tablets
0409010N0AAADAD
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 52,230 |
|
Co-careldopa 25mg/100mg modified-release tablets
0409010N0AAAGAG
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 32,976 |
|
Co-careldopa 50mg/200mg modified-release tablets
0409010N0AAAEAE
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 9,702 |
|
Co-careldopa 25mg/250mg tablets
0409010N0AAACAC
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 1,686 |
|
Co-careldopa 10mg/100mg tablets
0409010N0AAAAAA
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 1,031 |
|
Co-careldopa 25mg/100mg/5ml oral suspension
0409010N0AAAUAU
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 122 |
|
Co-careldopa 12.5mg/50mg/5ml oral suspension
0409010N0AAAVAV
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 87 |
|
Co-careldopa 25mg/100mg/5ml oral solution
0409010N0AAAKAK
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 20 |
|
Co-careldopa 6.25mg/25mg/5ml oral suspension
0409010N0AAAPAP
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 13 |
|
Co-careldopa 3.125mg/12.5mg/5ml oral suspension
0409010N0AAAWAW
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 5 |
|
Co-careldopa 50mg/200mg/5ml oral suspension
0409010N0AAANAN
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 5 |
|
Levodopa 20mg/ml/Carbidopa monohydrate 5mg/ml intestinal gel
0409010N0AAARAR
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 2 |
|
Co-careldopa 10mg/100mg/5ml oral suspension
0409010N0AAAJAJ
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
|
Co-careldopa 10mg/40mg/5ml oral suspension
0409010N0AAAYAY
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
|
Co-careldopa 2.5mg/10mg/5ml oral suspension
0409010N0AAAQAQ
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
|
Co-careldopa 25mg/250mg/5ml oral suspension
0409010N0AAAIAI
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
|
Co-careldopa 5mg/50mg/5ml oral suspension
0409010N0AAAXAX
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
|
Co-careldopa 625microgram/2.5mg/5ml oral suspension
0409010N0AAATAT
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.